To print: Select File and then Print from your browser's menu

Title: High Body Mass Index and Hepatitis C Are Risk Factors for Posttransplant Diabetes: Presented at WTC

"High Body Mass Index and Hepatitis C Are Risk Factors for Posttransplant Diabetes: Presented at WTC"

By Charlene Laino BOSTON, MA -- July 31, 2006 -- Patients who are overweight or who have impaired fasting glucose or positive hepatitis C serology before renal transplantation are at high risk of developing new-onset diabetes mellitus, a multicenter observational study suggests. Kidney recipients who are administered tacrolimus rather than cyclosporine are also at risk for new-onset diabetes, reported Nassim Kamar, MD, transplant surgeon, Hospital Rangel, Toulouse, France. Dr. Kamar presented the findings here on July 26[^th at the World Transplant Congress (WTC).

The study, which enrolled 527 renal transplant recipients at 17 centers, was designed to identify the risk factors for new-onset diabetes in patients who receive a calcineurin inhibitor after kidney transplantation.

The average age of patients studied was 47.5 years and 61.1% of them were male. Nearly all (95.2%) were Caucasian, and 3.7% had positive hepatitis C serology. Of the total, 261 patients (49.5%) were administered cyclosporine and 266 (50.5%) were given tacrolimus.

Of the total, 7.0% of the patients developed new-onset diabetes mellitus, defined as a fasting plasma glucose of 7 mmol/L or greater or initiation of insulin or oral hypoglycemic therapy. Patients developed diabetes a median of 1.6 months after transplantation.

In univariate analysis, risk factors for new-onset diabetes mellitus were age, impaired fasting glucose (6.1-7 mmol/L) before transplant, 2 or more cardiovascular risk factors, positive hepatitis C serology, body mass index (BMI) > 25 kg/m² prior to and at the time of transplant, and tacrolimus therapy.

Patients treated with tacrolimus were more likely to develop diabetes (10.2% vs 3.8%, P = .006). The median time to the development of new-onset diabetes mellitus was 2.9 months in the cyclosporine arm and 0.9 months in the tacrolimus arm (P = .09).

Surprisingly, patients with a family history of diabetes were not at heightened risk of developing the condition themselves, the researchers reported.

Multivariate analysis showed that patients whose maximal BMI was higher than 25 kg/m² before transplantation were 5.1 times more likely to develop new-onset diabetes mellitus than those with lower BMIs (CI 95% 2.0-12.9).

Patients whose fasting glucose levels were 6.1 to 7 mmol/L before transplant, were 4.7 times more likely to develop diabetes than those who did not have impaired fasting glucose levels (CI 95% 1.4-15.3).

Finally, positive hepatitis C serology (OR = 4.7, CI 95% 1.2-17.4) and use of tacrolimus rather than cyclosporine (OR = 3.0, CI 95% 1.4-6.7) also raised the risk of new-onset diabetes mellitus.

Knowing which factors increase a renal transplant's risk of diabetes will allow clinicians to step up preventive efforts in susceptible patients, Dr. Kamar said.

[Presentation title: Incidence and Risk Factors for New Onset Diabetes Mellitus After Renal Transplantation: Results of the Multicentric Observational Study Diapason. Abstract 857]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.